Table. Demographic Characteristics of Participants in This Subset of the POSITIVES Cohort.
| Characteristic | Participants, No. (%) | OR (95% CI) | |
|---|---|---|---|
| Untreated (n = 63) | Received nirmatrelivr (n = 79) | ||
| Age, median (IQR), y | 45 (33-62) | 62 (51-71) | 1.52 (1.22-1.88)a |
| Sex | |||
| Female | 49 (77.8) | 59 (74.7) | 0.84 (0.39-1.84) |
| Male | 14 (22.2) | 20 (25.3) | 1 [Reference] |
| Race | |||
| Black or African American | 6 (9.5) | 10 (12.7) | 1.26 (0.42-3.78) |
| White | 43 (68.3) | 57 (72.2) | 1 [Reference] |
| Other or unknownb | 14 (22.2) | 12 (15.2) | 0.65 (0.27-1.54) |
| Ethnicity | |||
| Hispanic or Latino | 4 (6.3) | 6 (7.6) | 1 [Reference] |
| Non-Hispanic or non-Latino | 49 (77.8) | 67 (84.8) | 0.91 (0.24-3.40) |
| Other or unknown | 10 (15.9) | 6 (7.6) | 0.40 (0.08-2.02) |
| COVID-19 vaccines, median (IQR), No. | 3 (3-4) | 4 (3-5) | 1.23 (1.00-1.49) |
| Time since last vaccine, median (IQR), d | 224 (163-325) | 155 (83-248) | 0.997 (0.994-0.999) |
| mAb use | 0 | 0 | NA |
| Immunosuppressionc | |||
| Absent | 56 (88.9) | 57 (72.2) | 1 [Reference] |
| Present | 7 (11.1) | 22 (27.8) | 3.46 (1.19-10.05) |
| SARS-CoV-2 variant | |||
| BA.2d | 7 (11.1) | 9 (11.4) | 1 [Reference] |
| BA.5e | 19 (30.2) | 21 (26.6) | 0.61 (0.17-2.16) |
| XBBf | 20 (31.7) | 30 (38.0) | 0.76 (0.22-2.63) |
| Other | 15 (23.8) | 13 (16.4) | 0.56 (0.13-2.32) |
| Not yet sequenced | 2 (3.2) | 6 (7.6) | 1.67 (0.13-20.58) |
| Virologic rebound | |||
| Absent | 60 (95.2) | 56 (70.9) | 1 [Reference] |
| Present | 3 (4.8) | 23 (29.1) | 6.46 (1.80-23.24) |
Abbreviations: mAb, monoclonal antibody; NA, not applicable; OR, odds ratio.
a
OR of age per 10 years between untreated and nirmatrelvir-treated groups.
b
Other or unknown includes American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander individuals.
c
Immunosuppression was determined by clinicians who conducted a formal medical record review in any participant who had an immunosuppressing condition or was taking an immunosuppressing medication.
d
BA.2 includes all BA.2 subvariants.
e
BA.5 includes all BA.5 subvariants.
f
XBB includes all XBB subvariants.